
Anton L. Pozniak, MD, FRCP, discusses the need for novel next-generation of NNRTIs, the future of this drug class, and current NNRTIs in clinical development.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the strengths and limitations of the first-generation NNRTIs
- Discuss data from randomized clinical trials investigating next-generation NNRTIs
- Describe next-generation NNRTIs in early clinical and preclinical development